How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

789 results for

Lidocaine Patch

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Summary of General Palliative Care Guidelines for the Management of Pain at the End of Life for Adults

or an anticonvulsant • Tricyclic Antidepressants e.g. amitriptyline 10mg nocte and increase gradually every 5-7 days to a maximum of 75mg nocte. Caution: known cardiac disease. • Anticonvulsants e.g. Pregabalin (starting dose 25-75mg Bd), or Gabapentin (starting dose 100mg tdS) SECOND LINE – combine a tricyclic antidepressant and anticonvulsant. Also consider • Lidocaine 5% patches applied 12hrly over the area of maximal pain • Capsaicin applied topically to painful area • Corticosteroids –e.g. dexamethasone 8mg (...) /6 of 24 hour morphine dose SeCond line StronG oPioidS • ORAL e.g oxycodone, hydromorphone, • TRANSDERMAL e.g fentanyl Patch * See over • PARENTERAL - e.g. oxycodone, alfentanil , fentanyl, hydromorphone Note: Avoid Cyclimorph® (cyclizine/morphine)injection in end of life care Breakthrough (PRN) analgesia in addition to regular strong opioids patients should have access to breakthrough analgesia- traditionally approximately 1/6 (one sixth) of the total daily dose. for management of incident

2011 Regulation and Quality Improvement Authority

282. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology (PubMed)

specific medications to treat pain. Current guidelines recommend treatment of postherpetic neuralgia in a hierarchical manner, with calcium channel α2-δ ligands (gabapentin and pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine), or topical lidocaine patches as first-line drugs. The safety and tolerability of pharmacologic therapies for pain are important issues to consider as postherpetic neuralgia affects primarily an older population. Patients should be educated

Full Text available with Trip Pro

2016 Journal of multidisciplinary healthcare

283. A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines

menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies (...) previously been treated with dermal filler in the perioral areas within the past year A patient that with a history of allergic reaction to a dermal filler or lidocaine A patient that with a history of a permanent filler to the perioral areas A female patient who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence

2016 Clinical Trials

284. The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy

opioids Patients treated with lidocaine patch Psychic Disorder Additive Conduct vis-à-vis alcohol or mind-altering substances Pregnant or breastfeeding women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02969733 Locations Layout table for location (...) : September 12, 2017 Last Verified: September 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by University Hospital, Lille: postoperative analgesia PainMatcher Additional relevant MeSH terms: Layout table for MeSH terms Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Signs and Symptoms Ketamine Lidocaine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs

2016 Clinical Trials

285. Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF

and of childbearing potential, a negative urine pregnancy test and agree to use adequate contraception. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years) must have a negative urine pregnancy test and must be willing to use a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive (...) or hypertrophic scars. Any infection or wound on the face. Allergic history including anaphylaxis or multiple severe allergies to natural rubber latex or lidocaine. Aspirin or nonsteroidal anti-inflammatory drugs within 1 week (7 days) prior to treatment. Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders. Over-the-counter (OTC) wrinkle products or prescription wrinkle treatments within 4 weeks (28 days) prior to treatment and throughout

2016 Clinical Trials

286. Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging

Lidocaine 5%; RLD Not Applicable Detailed Description: Subjects will be screened prior to dosing to ensure subjects meet all inclusion exclusion criteria. The test materials will be tested simultaneously. Skin sites on the paraspinal region will be utilized for application. The test sites will be randomized among the individual subjects according to their assigned identification number. All patches will be applied and removed by the laboratory staff. Due to safety concerns, it is not recommended (...) to simultaneously apply two whole, active, Lidocaine Patch 5% patches on the same subject during the 21-day period. The optimum design of this study will depend on the design of the test product patch. Since the RLD has a matrix design that can be safely cut, one-fourth of the patch can be used for these studies. If the test product patch also has a design that can be cut to a smaller size, it should also be cut in one-fourth and one-fourth of the test product patch applied simultaneously with one-fourth

2016 Clinical Trials

287. Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF

18, 2018 Sponsor: Prollenium Medical Technologies Inc. Information provided by (Responsible Party): Prollenium Medical Technologies Inc. Study Details Study Description Go to Brief Summary: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (with Lidocaine) versus Revanesse® Ultra for the Correction of Nasolabial Folds to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine, hereafter referred (...) to as Revanesse Ultra +) to Revanesse Ultra for subjects undergoing correction of nasolabial folds (NLFs) Condition or disease Intervention/treatment Phase Nasolabial Fold Correction Device: Revanesse Ultra+ (with lidocaine) Device: Revanesse Ultra Not Applicable Detailed Description: This is a randomized, multicenter, double-blind, split-face study in subjects seeking nasolabial fold correction. Subjects will be treated with Revanesse Ultra + in the NLF on one side of the face and Revanesse Ultra in the NLF

2016 Clinical Trials

288. Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis

Study Details Study Description Go to Brief Summary: Iontophoresis is a transdermal drug-delivery technique that enhances the transport of ionic species across membranes and may have significant benefit for the treatment of actinic keratosis (AK) by ablative fractional laser-primed photodynamic therapy (AFL-PDT). Condition or disease Intervention/treatment Phase Actinic Keratosis Drug: lidocaine/prilocaine (5%) application Device: 2940-nm Er:YAG AFL pretreatment Drug: MAL application Device (...) Date : June 2014 Actual Primary Completion Date : December 2015 Actual Study Completion Date : December 2015 Resource links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Group A (short-time iontophoresis group) Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h) Drug: lidocaine/prilocaine (5%) application For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra

2016 Clinical Trials

289. TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

: --Skin phototype of Fitzpatrick Type I-IV For FEMALE SUBJECT OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings (...) . A subject with an active bacterial, fungal, or viral infection in the treatment area. A subject with known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family sedation medication. A subject with known allergy or sensitivity to propylene glycol or any other ingredient of topical TR-987 or placebo. A subject receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or E

2016 Clinical Trials

290. Comparison of the Efficacy of the Ultrasound With Fluoroscopy in Guidance of Lumbar Sympathetic Block

Block (LSB) The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position. Device: Ultrasound for Lumbar Sympathetic Block (LSB) Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra (...) intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle. Procedure: Temperature measurement for Lumbar Sympathetic Block (LSB) Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min. Procedure: Postprocedure care for LSB Adverse events

2016 Clinical Trials

291. Topical Anesthesia for Removal of Stitches After Total Knee Arthroplasty

, 2016 Sponsor: National Taiwan University Hospital Information provided by (Responsible Party): National Taiwan University Hospital Study Details Study Description Go to Brief Summary: Lidocaine patch is a safe and effective topical anesthetic agent for removal of metal staples after total knee replacement Condition or disease Intervention/treatment Phase Metal Staple Removal After Total Knee Replacement Drug: Lidocaine patch Drug: placebo Not Applicable Detailed Description: This is a double-blind (...) : Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Prevention Official Title: Topical Anesthesia With Lidocaine Patch for Removal of Metal Staples After Total Knee Arthroplasty: A Prospective Randomized Trial Study Start Date : April 2016 Estimated Primary Completion Date : June 2016 Estimated Study Completion Date : June 2016 Resource links provided by the National Library of Medicine related topics: available for: Arms

2016 Clinical Trials

292. Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function

and effective birth control method from the first dose and for 8 days following administration of study drug. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm, intrauterine device (IUD), condom, surgical sterilization, and progestin implant or injection. Prohibited methods include: the rhythm method or withdrawal. BMI ≥ 18 ≤ 32 ; ± 20% for BMI-matched controls Clinical laboratory values (...) ester based anesthetics including cocaine HCl, procaine, tetracaine, chloroprocaine, dibucaine, or benzocaine amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are : lidocaine, mepivicaine, bupivicaine, levobupivicaine, ropivicaine, etidocaine, prilocaine, and articaine. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole

2016 Clinical Trials

293. PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function

and effective birth control method from the first dose and for 8 days following administration of study drug. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm, intrauterine device (IUD), condom, surgical sterilization, and progestin implant or injection. Prohibited methods include: the rhythm method or withdrawal. BMI ≥ 18 ≤ 42 (see Appendix); ± 20% for BMI-matched controls In general, good (...) within the laboratory's stated normal range; if not within this range, they must be without any clinical significance. Exclusion Criteria: Has a known allergy to any ester based anesthetics including cocaine HCl, procaine, tetracaine, chloroprocaine, dibucaine, or benzocaine amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are : lidocaine, mepivicaine, bupivicaine, levobupivicaine, ropivicaine, etidocaine, prilocaine, and articaine. Concurrent use of medications known

2016 Clinical Trials

294. Phase I Pharmacokinetic Study of RX0041-2

and ≤ 32 at the screening visit. Females (if of child-bearing potential and sexually active) and males (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method from the first dose and for 8 days following administration of study drug. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm, intrauterine device (...) , chloroprocaine, dibucaine, or benzocaine Amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are: Lidocaine, mepivicaine, bupivicaine, levobupivicaine, ropivicaine, etidocaine, prilocaine, and articaine. The use of amphetamines, methylphenidate or other stimulant prescription and nonprescription products such as pseudoephedrine, bronchial inhalers containing sympathomimetics (epinephrine or other beta-receptor agonist) or herbal products in the 7 days prior to screening or has

2016 Clinical Trials

295. A Study Investigating the Effects of Niagenâ„¢ in Healthy Adults.

, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner Healthy as determined by laboratory results, medical history, and physical exam Agrees to comply with study procedure Agrees to maintain current level of physical activity throughout the study and avoid exercising on the day of study visits 3 to 7 (prior (...) or sensitivity to lidocaine Bleeding disorder Serum creatinine ≥ 130µmol/L for males and ≥ 125µmol/L for female Individuals who are cognitively impaired and/or who are unable to give informed consent Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or which may pose significant risk to the subjects Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2016 Clinical Trials

296. Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence. (PubMed)

topical treatments are currently licensed: lidocaine 5% medicated plaster (post-herpetic neuralgia) and the capsaicin 8% patch (peripheral NP). When compared head to head with the oral standard of care (pregabalin), the lidocaine 5% medicated plaster provided similar relief of pain associated with post-herpetic neuralgia but did not meet the primary predefined criteria for noninferiority. The capsaicin 8% patch, however, demonstrated noninferior efficacy when compared head-to-head with pregabalin

Full Text available with Trip Pro

2016 Journal of pain and symptom management

297. First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review and network meta-analysis. (PubMed)

was estimated to be the most effective (mean difference -25.42 (95 % CI -32.25, -18.57). Other members of the 'caine' family were also estimated to be more effective than no treatment as were Ametop®, EMLA® and Rapydan® patch. The meta-analysis compared the pain of anaesthetic application with the unattenuated pain of cannulation. This found that all applications of local anaesthetic were less painful than cannulation without local anaesthetic. In particular a 1 % lidocaine injection was estimated (...) visual analogue scale.The systematic review found 37 includable studies, 27 of which were suitable for network meta-analysis and two for random-effects meta-analysis. The results of the network meta-analysis indicate that none of the 17 anaesthetic considered had a very high probability of being the most effective when compared to each other; 2 % lidocaine had the highest probability (44 %). When the anaesthetics were compared to no treatment, the network meta-analysis showed that again 2 % lidocaine

Full Text available with Trip Pro

2016 BMC anesthesiology

298. Neuropathic low back pain in clinical practice. (PubMed)

and NSAIDs, although widely used for LBP, are unlikely to ameliorate the neuropathic component and data on the use of NP medications such as antidepressants and gabapentin/pregabalin are limited. While there is an unmet need for improved treatment options, recent data have shown tapentadol to have efficacy in the neuropathic component of LBP, and studies suggest that the capsaicin 8% patch and lidocaine 5% medicated plaster, topical analgesics available for the treatment of peripheral NP, may (...) and topical analgesics - such as the capsaicin 8% patch and the lidocaine 5% medicated plaster - may be effective options for the treatment of neuropathic low back pain in defined patient groups.© 2016 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC®.

Full Text available with Trip Pro

2016 European Journal of Pain

300. Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin (PubMed)

potential change. The ATX response was completely inhibited by tetrodotoxin suggesting that the ATX response was solely derived from hNav1.7 activation, which was consistent with the results where ATX produced a negligible response in null HEK-293 cells. Six VGSC antagonists including lidocaine, lamotrigine, phenytoin, carbamazepine, riluzole, and 2-amino-6-trifluoromethylthiobenzothiazole all concentration-dependently inhibited ATX response with IC50 values comparable to that reported from patch-clamp

Full Text available with Trip Pro

2016 Marine drugs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>